🧫
cGAMP biomarker analysis in ALS patient spinal cord samples
active
experiment
Created: 2026-04-06T12:28:40
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-820a16b5-8133-478d-a80d-2218d0225336
🧫 Experiment Protocol
ExploratoryAmyotrophic Lateral SclerosisTARDBPHuman ALS patient spinal cord tissueproposed
Post-mortem analysis of spinal cord samples from ALS patients to measure levels of cyclic GMP-AMP (cGAMP), the specific metabolite produced by cGAS enzyme activation. This study aimed to validate the clinical relevance of the cGAS/STING pathway in human ALS pathology by demonstrating elevated cGAMP levels as a potential biomarker of mitochondrial DNA release and cGAS/STING activation. The analysis provided crucial translational evidence connecting the mechanistic findings from cellular and animal models to human disease pathology.
PRIMARY OUTCOME
Elevated cGAMP levels as biomarker
EXPECTED OUTCOMES
ALS patients should show significantly elevated cGAMP levels compared to controls, indicating active cGAS/STING signaling
SUCCESS CRITERIA
Statistically significant elevation of cGAMP levels in ALS patient samples versus controls
PROTOCOL
Post-mortem spinal cord tissue collection, cGAMP quantification assays, comparison between ALS patients and controls, correlation with TDP-43 pathology
LINKED HYPOTHESES
Source: PMID 33031745 ↗
🧫 Experiment Extras
PATHWAY
cGAS/STING pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.